Update: Merck KGaA, Pfizer score landmark FDA nod for checkpoint contender Avelumab






This is an update to my story: “German Merck, flying under Street’s radar, gets no respect; but not for long” Germany’s Merck KGaA and part­ner Pfizer Inc. came away with… Read more »

PTC Therapeutics catches falling knife with Emflaza buy; or did it?






Every now and again I’ll read about what seems on its face a boneheaded business deal between two Pharma companies and try to blow the lid off some super-stealthy, strategic,… Read more »

Indy’s Eli Lilly making noise with cancer push; Brickyard neighbor revving its drug-discovery engine






I’ve been to the headquarters of Eli Lilly & Co.–about 15 minutes (or about 5 miles) from the “Brickyard” where the Indianapolis 500 is run each year. The racing is… Read more »

Week’s opening stock salvo: Esperion, Nektar, CytomX soar; Aevi Genomic thrashed






Esperion Therapeutics Inc. (Nasdaq: ESPR) stock recently recovered big time from last Amgen-induced beat down to touch an 18-month high after the company outlined its path to FDA approval for its… Read more »

After 15 years, unheralded French biotech eyeing big payday on cancer breakthrough; “buy” signal–solid






Hidden from view just across the French border from Geneva is a little-known (at least here in the US) biotech eyeing long-awaited FDA approval for a nuclear medicine targeting the… Read more »

Health sector’s biggest winners & losers as of March 17, 2017






Seres Therapeutics Inc. (Nasdaq: MCRB) led advancing issues, soaring $2.71, or 29% for the week, to $12.04. The small microbiome-therapeutics platform company released its fourth-quarter results earlier Thursday (March 16,… Read more »

Reasons why Valeant/Ackman divorce better than staying in a bad marriage






Steve’s Take: [“Life is far too short to spend it immersed in an unhealthy relationship.”—Jeffrey M. Cohen, Esq., professional mediator.] This week (March 13, 2017), billionaire Bill Ackman exited one… Read more »

GOP can’t handle the truth: millions to lose coverage under Trumpcare






Steve’s Take: Remember President Trump’s pre- and post-election promise, no, it sounded more like a guarantee, of “insurance for everybody?” Then last week, the Trump-backed House bill, when finally unveiled… Read more »

Canon eyeing big bite into healthcare apple with Toshiba Medical buy; shares primed for rebound?






Steve’s Take: Late last year, the Japanese tech giant Canon Inc. quietly acquired Toshiba Medical Systems Corp., a leading manufacturer and seller of medical imaging devices. The move thrusts Canon… Read more »

German Merck, flying under Street’s radar, gets no respect; but not for long






Steve’s Take: Wall Street analysts are perhaps familiar with the history behind the two Pharma powerhouses, US-based Merck & Co., and Germany-based Merck KgaA. Until recently, however, I only had… Read more »